logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

The U.S. FDA Approved BioMarin Pharmaceutical's ROCTAVIAN, the First and Only Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical US FDA Approved ROCTAVIAN BioMarin Pharmaceutical ( BMRN ) announced that the U.S. FDA approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A without antibodies to adeno-associated virus serotype 5 ( AAV5 ) detected by...

Read More

June 30, 2023

0

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR  Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85% AstraZeneca ( AZN ) and Amgen ( AMGN )...

Read More

May 14, 2021

0

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

Sanofi and GlaxoSmithKline COVID-19 Vaccine Sanofi ( SNY ) and GlaxoSmithKline ( GSK ) COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in the Phase 2 trial.  Sanofi's and GlaxoSmithKline's adjuvanted recombinant COVID-19 vaccine candidate achieved...

Read More

May 17, 2021

0

Why Investors Have Enthusiasm for CureVac N.V.

CureVac N.V. in the News CureVac N.V. ( CVAC ) announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March...

Read More

January 10, 2023

0

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

Recursion Pharmaceuticals Product REC-163964 Recursion Pharmaceuticals Inc ( RXRX ) announced the initiation of an investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential...

Read More

May 25, 2021

0

The U.S. FDA Approved BioMarin’s ROCTAVIANTM, the First and Only Gene Therapy for Adults with Severe Hemophilia A in the US

BioMarin Pharmaceutical US FDA Approval for ROCTAVIAN On June 30, 2023, BioMarin Pharmaceutical ( BMRN ) announced that the U.S. FDA has approved ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) gene therapy for adults with severe hemophilia A (congenital factor VIII ( FVIII )...

Read More

July 6, 2023

0

Ionis and Royalty Pharma Enter into a Royalty Agreement for Up to $1.1B

Ionis Pharmaceuticals and Royalty Pharma Ionis Pharmaceuticals ( IONS ) and Royalty Pharma plc ( RPRX ) announced that Royalty Pharma has acquired an interest in Ionis' royalty in Biogen's SPINRAZA® (nusinersen) and Novartis' pelacarsen for up to $1.125 billion, including an...

Read More

January 13, 2023

0

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

Aptevo Therapeutics Inc in the News Aptevo Therapeutics Inc ( APVO ) has positive results from the Phase 1 dose-escalation trial evaluating its lead ADAPTIR candidate product APVO436 for the treatment of acute myeloid leukemia ( AML ) and myelodysplastic...

Read More

May 26, 2021

0

GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

GlaxoSmithKline and Vir Biotechnology are Granted an EUA for Sotrovimab GlaxoSmithKline ( GSK ) and Vir Biotechnology ( VIR ) announced the U.S. FDA has granted an Emergency Use Authorization ( EUA ) for sotrovimab (formerly VIR-7831) - an investigational...

Read More

May 27, 2021

0

Treating Cancers Resistant to ALL Drugs a Priority for Researchers. See What Merck and Kintara Have Done

Merck and Kintara in the NEWS Treating cancers that have no treatments should be a priority for researchers to create a treatment for them.  Patients who are afflicted with untreatable deadly diseases might not have a single drop of hope...

Read More

July 20, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 44
  • 45
  • 46
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy